Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 21Neurofibromatosis 1 19Neurofibroma, Plexiform 11Melanoma 11Lung Neoplasms 8Neoplasms 7Neoplasm Metastasis 7Colorectal Neoplasms 7Breast Neoplasms 7Solid Tumours 5Pancreatic Neoplasms 5Carcinoma, Hepatocellular 4Uveal Melanoma 3Triple Negative Breast Neoplasms 3Thyroid Neoplasms 3Rectal Neoplasms 3Neurofibrosarcoma 3Gallbladder Neoplasms 3Colonic Neoplasms 3Biliary Tract Neoplasms 3Thyroid Cancer, Papillary 2Sarcoma 2Bile Duct Neoplasms 2Adult Solid Neoplasm 2Thyroid Diseases 1Thymoma 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma, Kaposi 1Renal Insufficiency 1

Interventions

Acupuncture Therapy 10Exercise 7Cryotherapy 6Paclitaxel 5Glutamine 5Surveys and Questionnaires 3Duloxetine Hydrochloride 3Dexamethasone 3Bortezomib 3Acetylcysteine 3Thioctic Acid 2Tablets 2Sodium Chloride 2Saline Solution 2Physical Therapy Modalities 2Low-Level Light Therapy 2Lenalidomide 2Fish Oils 2Fatty Acids, Omega-3 2ziconotide 1sagopilone 1pembrolizumab 1nicotinamide-beta-riboside 1nabilone 1glutamic acid diethyl ester 1eribulin 1enfortumab vedotin 1allantoicase 1Yoga 1XELOX 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Peripheral Nervous System Diseases × AZD 6244 × Clear all
NCT03109301 2019-04-05

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn
CNS

Neoplasms, Nerve Tissue, Neurofibromatosis 1, Peripheral Nervous System Diseases, Neurofibroma, Plexiform, Heredodegenerative Disorders, Nervous System

Data powered by HemOnc (CC BY 4.0) Colophon âš¡